Periostin ELISA Assay Kit

$590.00

The Periostin ELISA Assay Kit (enzyme-linked immunoassay kit) is intended for the quantitative determination of human periostin levels in serum or plasma samples. The Eagle Biosciences Human Periostin ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

SKU: BI-20433 Categories: , ,

Human Periostin ELISA Assay Kit

Periostin ELISA Assay Kit Developed and Manufactured in Austria by Biomedica

Size: 1×96 wells
Sensitivity: LOD: 20 pmol/l (0 pmol/l + 3 SD); LLOQ: 62.5 pmol/l
Dynamic Range: 0 – 4000 pmol/l
Incubation Time: 5.5 hours
Sample Type: Serum, plasma (EDTA, heparin, citrate)
Sample Size: 150 µL
Alternative Names: OSF-2, POSTN, OSF2, PDLPN, PN
For Research Use Only
Controls Included


Unit conversion: 1 pg/ml = 0.011 pmol/l (MW: 91 kDa)
Cross Reactivity: Due to the high sequence homology between human Periostin and Periostin of other species, the antibodies utilized in the assay may cross react with mouse, rat, cynomolgous monkey, dog and cat Periostin.


Assay Principle

The Periostin ELISA kit is a sandwich enzyme immunoassay for the quantitative determination of periostin in human serum and plasma samples. In a first step, pre-diluted standard/control/sample and biotinylated polyclonal goat anti-human Periostin antibody are pipetted into the wells of the microtiter strips, which are pre-coated with mouse monoclonal anti-human Periostin antibody. Periostin present in the standard/control/sample binds to the pre-coated antibody in the well and forms a sandwich with the detection antibody. In a washing step all non-specific unbound material is removed. In a second step, the conjugate (streptavidin-HRP) is pipetted into the wells and reacts with the detection antibody. After another washing step, the substrate (TMB, tetramethylbenzidine) is pipetted into the wells. The enzyme-catalyzed color change of the substrate is directly proportional to the amount of Periostin present in the sample. This color change is detectable with a standard microtiter plate reader. A dose response curve of the absorbance (optical density, OD at 450 nm) vs. standard concentration is generated, using the values obtained from the standard. The concentration of human Periostin in the sample is determined directly from the dose response curve.


Related Products

Osteoprotegerin ELISA Assay Kit
Soluble Semaphorin 4D ELISA
Activated Carboxylated Osteocalcin ELISA

Additional Information

Assay Background


Periostin (OSF-2) is secreted as a 91 kDa homodimeric soluble extracellular matrix protein expressed in collagen-rich fibrous connective tissues. Periostin is involved in osteoblast recruitment, attachment and spreading. It has been associated with the epithelial-mesenchymal transition in cancer and with the differentiation of mesenchyme in the developing heart. Periostin has functions in osteology, tissue repair, oncology, cardiovascular and respiratory diseases, and in various inflammatory settings. There are at least 7 isoforms of Periostin, caused by alternative splicing (https://www.uniprot.org/uniprot/Q15063).

Assay Procedure


  1. Add 150 µl pre-diluted (1+50) STD/CTRL/SAMPLE (see chapter 5) reagents and sample preparation) into each well, swirl gently.
  2. Cover tightly and incubate for 2 hours at room temperature (18-26°C).
  3. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  4. Add 150 µl AB (biotinylated anti periostin antibody, green cap) into each well, swirl gently.
  5. Cover tightly and incubate for 2 hours at room temperature (18-26°C).
  6. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  7. Add 150 µl CONJ (Conjugate, amber cap) into each well, swirl gently.
  8. Cover tightly and incubate for 1 hour at room temperature (18-26°C).
  9. Aspirate and wash wells 5x with 300 µl diluted WASHBUF (Wash buffer). After final wash, remove remaining WASHBUF by strongly tapping plate against paper towel.
  10. Add 150 µl SUB (Substrate, blue cap) into each well, swirl gently.
  11. Incubate for 30 min at room temperature (18-26°C) in the dark.
  12. Add 50 µl STOP (Stop solution, white cap) into each well, swirl gently.
  13. Measure absorbance immediately at 450 nm with reference 630 nm, if available.

periostin-elisa-assay-kit

periostin-elisa-assay standard curve

Expected Values


Values from apparently healthy individuals:

  • Median serum (n=24): 864 pmol/l
  • Median EDTA plasma (n=20): 817 pmol/l
  • Median heparin plasma (n=20): 891 pmol/l
  • Median citrate plasma (n=24): 885 pmol/l

It is recommended to establish the normal range for each laboratory.

Literature


  • The role of periostin in tissue remodeling across health and disease. Conway SJ et al., Cell Mol Life Sci, 2014; 71(7): 1279-1288.
  • Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. Rousseau JC et al., J Clin Endocrinol Metab, 2014; 2533-2539.
  • Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Sakellariou GT et al., Rheumatology, 2015; 54: 908-914.
  • Serum Periostin: A Novel Biomarker for Asthma Management. Hisako Matsumoto, Allergology International, 2014; 63:153-160.
  • Serum periostin in obstructive airways disease. Fingleton J et al., Eur Respir J 2016; 44. Doi 10.1183/13993003.01384-2015.
  • Levels of Blood Periostin Decrease After Acute Myocardial Infarction and Are Negatively Associated With Ventricular Function After 3 Months. Cheng CW et al., J Investig Med, 2015; 60: 523-528.
  • Discoidin domain receptor-1 and periostin: new players in chronic kidney disease. Alfieri C et al, Nephrol Dial Transplant, 2015; 30: 1965-1971.
  • Overexpression of periostin in stroma positively associated with aggressive prostate cancer. Tian Y et al., PLoS One, 2015; 17; 10(3):e0121502.
  • Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med, 2011; 28(2):181-186.
  • Tissue expression and serum levels of periostin during pregnancy: A new biomarker of embryo-endometrial cross talk at implantation. Morelli M et al., PLoS One, 2015; 17;10(3):e0121502.

Manual

Product Manual


Publications

Citations


  • The role of periostin in tissue remodeling across health and disease. Conway SJ et al., Cell Mol Life Sci, 2014; 71(7): 1279-1288.
  • Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. Rousseau JC et al., J Clin Endocrinol Metab, 2014; 2533-2539.
  • Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation. Sakellariou GT et al., Rheumatology, 2015; 54: 908-914.
  • Serum Periostin: A Novel Biomarker for Asthma Management. Hisako Matsumoto, Allergology International, 2014; 63:153-160.
  • Serum periostin in obstructive airways disease. Fingleton J et al., Eur Respir J 2016; 44. Doi 10.1183/13993003.01384-2015.
  • Levels of Blood Periostin Decrease After Acute Myocardial Infarction and Are Negatively Associated With Ventricular Function After 3 Months. Cheng CW et al., J Investig Med, 2015; 60: 523-528.
  • Discoidin domain receptor-1 and periostin: new players in chronic kidney disease. Alfieri C et al, Nephrol Dial Transplant, 2015; 30: 1965-1971.
  • Overexpression of periostin in stroma positively associated with aggressive prostate cancer. Tian Y et al., PLoS One, 2015; 17; 10(3):e0121502.
  • Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med, 2011; 28(2):181-186.
  • Tissue expression and serum levels of periostin during pregnancy: A new biomarker of embryo-endometrial cross talk at implantation. Morelli M et al., PLoS One, 2015; 17;10(3):e0121502.